Table 2.

Side population is enriched with tumorigenic cells

Cell typeCell injected (n)Tumor incidence (latency)
U373-SP-l° *1,0001/1 (33 d)
U373-NSP-1°50,0000/1 (terminated in 7 mo)
U373-SP-2° 1007/11 (34-48 d)
1,0001/1 (39 d)
U373-NSP-2°50,0000/1 (terminated in 7 mo)
200,0000/1 (terminated in 7 mo)
MCF7-SP *1,0001/6 (160 d)
10,0003/6 (130-150 d)
MCF7-NSP10,0001/6 (194 d)
250,0001/2 (190 d)
LAPC9-SP 1002/8 (52 and 108 d)
1,0003/4 (108 d)
1,5002/2 (41 and 72 d)
LAPC9-NSP150,0000/1 (terminated in 9 mo)
300,0001/1 (92 d)
  • NOTE: Tumor incidence refers to the number of tumors/the number of injections. Latency refers to the time from tumor cell injection to the appearance of a palpable tumor.

  • * Cultured cells: 1° and 2° refer to the first and second-generation tumors, respectively.

  • Xenograft tumor-derived cells.